S&P 500   4,034.13 (+1.93%)
DOW   34,251.05 (+1.18%)
QQQ   289.36 (+3.13%)
AAPL   145.98 (+3.41%)
MSFT   249.61 (+3.86%)
META   116.30 (+6.25%)
GOOGL   99.45 (+4.48%)
AMZN   94.65 (+2.41%)
TSLA   189.71 (+4.91%)
NVDA   163.81 (+4.74%)
NIO   12.76 (+21.52%)
BABA   88.48 (+10.79%)
AMD   76.07 (+3.65%)
T   19.03 (+0.11%)
MU   56.80 (+3.05%)
CGC   3.54 (+3.51%)
F   13.79 (+0.29%)
GE   85.53 (-0.15%)
DIS   96.53 (+1.94%)
AMC   7.27 (-2.15%)
PYPL   78.21 (+0.73%)
PFE   49.49 (+0.00%)
NFLX   303.70 (+8.09%)
S&P 500   4,034.13 (+1.93%)
DOW   34,251.05 (+1.18%)
QQQ   289.36 (+3.13%)
AAPL   145.98 (+3.41%)
MSFT   249.61 (+3.86%)
META   116.30 (+6.25%)
GOOGL   99.45 (+4.48%)
AMZN   94.65 (+2.41%)
TSLA   189.71 (+4.91%)
NVDA   163.81 (+4.74%)
NIO   12.76 (+21.52%)
BABA   88.48 (+10.79%)
AMD   76.07 (+3.65%)
T   19.03 (+0.11%)
MU   56.80 (+3.05%)
CGC   3.54 (+3.51%)
F   13.79 (+0.29%)
GE   85.53 (-0.15%)
DIS   96.53 (+1.94%)
AMC   7.27 (-2.15%)
PYPL   78.21 (+0.73%)
PFE   49.49 (+0.00%)
NFLX   303.70 (+8.09%)
S&P 500   4,034.13 (+1.93%)
DOW   34,251.05 (+1.18%)
QQQ   289.36 (+3.13%)
AAPL   145.98 (+3.41%)
MSFT   249.61 (+3.86%)
META   116.30 (+6.25%)
GOOGL   99.45 (+4.48%)
AMZN   94.65 (+2.41%)
TSLA   189.71 (+4.91%)
NVDA   163.81 (+4.74%)
NIO   12.76 (+21.52%)
BABA   88.48 (+10.79%)
AMD   76.07 (+3.65%)
T   19.03 (+0.11%)
MU   56.80 (+3.05%)
CGC   3.54 (+3.51%)
F   13.79 (+0.29%)
GE   85.53 (-0.15%)
DIS   96.53 (+1.94%)
AMC   7.27 (-2.15%)
PYPL   78.21 (+0.73%)
PFE   49.49 (+0.00%)
NFLX   303.70 (+8.09%)
S&P 500   4,034.13 (+1.93%)
DOW   34,251.05 (+1.18%)
QQQ   289.36 (+3.13%)
AAPL   145.98 (+3.41%)
MSFT   249.61 (+3.86%)
META   116.30 (+6.25%)
GOOGL   99.45 (+4.48%)
AMZN   94.65 (+2.41%)
TSLA   189.71 (+4.91%)
NVDA   163.81 (+4.74%)
NIO   12.76 (+21.52%)
BABA   88.48 (+10.79%)
AMD   76.07 (+3.65%)
T   19.03 (+0.11%)
MU   56.80 (+3.05%)
CGC   3.54 (+3.51%)
F   13.79 (+0.29%)
GE   85.53 (-0.15%)
DIS   96.53 (+1.94%)
AMC   7.27 (-2.15%)
PYPL   78.21 (+0.73%)
PFE   49.49 (+0.00%)
NFLX   303.70 (+8.09%)
NASDAQ:LIFE

aTyr Pharma - LIFE Stock Forecast, Price & News

$2.15
+0.02 (+0.94%)
(As of 11/30/2022 02:34 PM ET)
Add
Compare
Today's Range
$2.11
$2.15
50-Day Range
$2.11
$3.05
52-Week Range
$2.06
$8.78
Volume
27 shs
Average Volume
63,996 shs
Market Capitalization
$61.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

aTyr Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,061.1% Upside
$24.50 Price Target
Short Interest
Healthy
1.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of aTyr Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$21,400 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.82) to ($1.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

142nd out of 1,043 stocks

Biological Products, Except Diagnostic Industry

23rd out of 172 stocks

LIFE stock logo

About aTyr Pharma (NASDAQ:LIFE) Stock

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Stock News Headlines

aTyr Pharma (NASDAQ:LIFE) Upgraded to "Hold" by StockNews.com
aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
aTyr Pharma to Present at Upcoming Investor Conferences
LIFE aTyr Pharma, Inc.
aTyr Pharma, Inc. (LIFE)
aTyr Pharma: Q2 Earnings Insights
See More Headlines
Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Company Calendar

Last Earnings
8/09/2021
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/13/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:LIFE
CUSIP
53217V10
Employees
49
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$24.50
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+551.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-33,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10.45 million
Book Value
$2.69 per share

Miscellaneous

Free Float
27,377,000
Market Cap
$61.55 million
Optionable
Optionable
Beta
1.31

Social Links


Key Executives

  • Dr. Sanjay S. Shukla M.D. (Age 50)
    M.S., Pres, CEO & Director
    Comp: $816.41k
  • Ms. Jill M. BroadfootMs. Jill M. Broadfoot (Age 60)
    Chief Financial Officer
    Comp: $561.76k
  • Ms. Nancy E. Denyes Krueger (Age 54)
    Gen. Counsel & Corp. Sec.
    Comp: $537.59k
  • Xiang-Lei Yang Ph.D.
    Founder
  • Ms. Ashlee Dunston
    Director of Investor Relations & Corp. Communications
  • Mr. Peter Villiger
    VP of Corp. Devel.
  • Ms. Danielle Campbell
    VP of Human Resource
  • Dr. Leslie Nangle Ph.D.
    VP of Research
  • Dr. Ying J. Buechler Ph.D.
    Exec. Director of Biologics Devel. & Manufacturing
  • Dr. Melissa A. Ashlock (Age 64)
    Sr. Advisor













LIFE Stock - Frequently Asked Questions

Should I buy or sell aTyr Pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIFE shares.
View LIFE analyst ratings
or view top-rated stocks.

What is aTyr Pharma's stock price forecast for 2023?

2 brokers have issued 12-month target prices for aTyr Pharma's shares. Their LIFE share price forecasts range from $14.00 to $35.00. On average, they anticipate the company's share price to reach $24.50 in the next twelve months. This suggests a possible upside of 1,050.2% from the stock's current price.
View analysts price targets for LIFE
or view top-rated stocks among Wall Street analysts.

How have LIFE shares performed in 2022?

aTyr Pharma's stock was trading at $7.47 on January 1st, 2022. Since then, LIFE stock has decreased by 71.5% and is now trading at $2.13.
View the best growth stocks for 2022 here
.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 303,000 shares, a decline of 33.3% from the October 31st total of 454,600 shares. Based on an average trading volume of 83,600 shares, the short-interest ratio is presently 3.6 days.
View aTyr Pharma's Short Interest
.

When is aTyr Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our LIFE earnings forecast
.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) issued its quarterly earnings results on Monday, August, 9th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.13.

When did aTyr Pharma's stock split?

aTyr Pharma shares reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include VR Adviser LLC (37.38%), Telemetry Investments L.L.C. (1.72%), Renaissance Technologies LLC (0.66%), Marshall Wace LLP (0.61%), Dimensional Fund Advisors LP (0.59%) and Royal Bank of Canada (0.17%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends
.

How do I buy shares of aTyr Pharma?

Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $2.13.

How much money does aTyr Pharma make?

aTyr Pharma (NASDAQ:LIFE) has a market capitalization of $60.97 million and generates $10.45 million in revenue each year. The biotechnology company earns $-33,770,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The official website for the company is www.atyrpharma.com. The biotechnology company can be reached via phone at (858) 731-8389, via email at investorrelations@atyrpharma.com, or via fax at 858-731-8394.

This page (NASDAQ:LIFE) was last updated on 11/30/2022 by MarketBeat.com Staff